General Information
As of 05/25/2012
|
| NAV |
$29.78 |
| NAV Daily Change |
$0.16 |
| % Yield |
0 |
| % SEC Yield |
N/A |
| % YTD Return (as of 04/30/2012) |
17.40 |
| Objective* |
Equity - Sector Health |
| Peer* |
HL MG |
* Key
Portfolio Statistics
|
| % Unrealized Gain YTD |
29.40 |
| Net Assets (Mil $) N/A |
429.79 |
| % Turnover N/A |
54.00 |
Fees
|
| % Max Sales Load |
5.50 |
| % Min Sales Load |
.00 |
| % Max Deferred Load |
.00 |
Expenses
|
| % Max 12b-1 Fee |
.30 |
| % Max Management Fee |
.75 |
| % Redemption Fee |
.00 |
| % Expense Ratio |
1.25 |
Allocation
|
| Large Growth |
8.63 |
| Large Value |
.00 |
| Small Growth |
23.43 |
| Small Value |
.00 |
| Foreign Stock |
.00 |
| Emerging Market |
.00 |
| Precious Metals |
.00 |
| Intermediate Bond |
.00 |
| Foreign Bond |
39.78 |
| High Yield Bond |
.00 |
Portfolio Information |
| Composition |
| As of N/A |
% of Net Assets |
| Stock |
82.49 |
| Cash |
35.52 |
| Bonds |
.00 |
| Preferred |
1.03 |
| Convertibles |
.00 |
| Foreign Stock |
11.82 |
| Foreign Bonds |
.00 |
| Hedge |
.00 |
| Other |
-19.04 |
Sector / Country Weightings
|
| As of 02/29/2012 |
% of Portfolio |
| Health |
49.58 |
| Other |
24.22 |
| Services |
9.32 |
| Finance |
8.48 |
| Retail Trade |
4.51 |
| Industrial Cyclical |
3.07 |
| Technology |
.82 |
| N/A |
N/A |
| N/A |
N/A |
Portfolio Holdings |
Top Equity Holdings
(As of 02/29/2012) |
% of Portfolio |
Value (Mil$) |
|
| ALEXION PHARMACEUTICALS INC |
7.97 |
75.88 |
| BIOMARIN PHARMACEUTICAL |
4.66 |
44.37 |
| EXPRESS SCRIPTS INC |
3.89 |
37.00 |
| UNITEDHEALTH GROUP INC |
3.86 |
36.76 |
| VERTEX PHARMACEUTICALS INC |
3.16 |
30.10 |
| MEDIVATION INC |
3.04 |
28.91 |
| IMPAX LABORATORIES INC |
2.86 |
27.20 |
| ARIAD PHARMACEUTICALS |
2.85 |
27.11 |
| AMARIN CORP PLC |
2.43 |
23.08 |
| N/A |
N/A |
N/A |
|
|
This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Funds over the next 6 months.
| Zacks Rank |
Definition |
| #1 |
Strong Buy |
| #2 |
Buy |
| #3 |
Hold |
| #4 |
Sell |
| #5 |
Strong Sell |
| S&P |
500 |
Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Zacks Premium Research
|
Zacks Mutual Fund Rank
|
| |
Find similar funds that have a Mutual Fund Rank.
Find Similar Funds Now  |
Fund Description
|
Incepted in June 1999, this fund is managed by Prudential Investment. The objective of this fund is to seek long-term capital appreciation. The fund invests 80% of its investable assets in equity-related securities of U.S. companies within a specific group of industries. The fund buys securities of companies in the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and HMOs that derive a substantial portion of their sales from healthcare-related products or services. The fund offers dividends and capital gains annually.
|
Zacks Commentary for PHLAX
|
|
|
|
Stock Holding Statistics
% of Net Assets
|
| As Of |
N/A |
| Total Issues |
66 |
| Avg. P/E |
21.17 |
| Avg. P/Book |
5.11 |
| Avg. EPS Growth |
21.31 |
| Avg. Market Value (Mil $) |
12,338 |
Risk
|
|
3 Year |
5 Year |
10 Year |
| Beta |
1.01 |
0.87 |
0.80 |
| Alpha |
8.27 |
8.20 |
9.11 |
| R Squared |
0.65 |
0.64 |
0.55 |
| Std. Dev. |
19.70 |
20.69 |
17.29 |
| Sharpe |
1.56 |
0.42 |
1.00 |
Shareholder Information
|
| Manager |
David Chan |
| Since |
06/99 |
| Manager Rating * SEE EXPLANTION |
8.1 |
| Inception Date |
06/30/1999 |
| Shareholders |
20,319 |
| Dividends Paid |
A |
| Minimum Initial Investment |
$2,500 |
| Minimum Subsequent Investment |
$100 |
| IRA Minimum |
$1000 |
| IRA Available |
Y |
Check Writing |
N |
Phone Invest |
Y |
| Phone Exchange |
Y |
Phone Redeem |
Y |
Auto Invest |
Y |
| Wire Redeem |
N |
Wire Fee |
N |
Wire Transfer |
N |
Contact Information
|
| Family |
Prudential |
| Address |
PO Box 9655
Providence, RI 02940 |
| Phone |
800 225-1852 |
|
Sponsored Links 
